Prostate Health Index (phi)

An FDA-approved blood test to be used as an aid in distinguishing prostate cancer from benign prostatic conditions1

The Prostate Health Index (phi) is a calculation that uses a combination of three blood tests to produce a "phi score." This score provides more information about what elevated PSA levels might mean and the probability of finding prostate cancer on biopsy.*

This product may not be available in your country or region at this time. Please contact your Beckman Coulter sales representative or distributor for more information.

Video Here's What You Need to Know About phi

Why choose phi? Learn more by watching this video.

Watch now
Doctor with a hand on older smiling man discussing prostate cancer

Brochure The phi Clinical Summary

The superior performance of phi compared to PSA alone has been demonstrated through multiple peer-reviewed publications. Read summaries of the articles and discover the power of phi.

Download

1Loeb S, Sanda MG, Broyles DL, et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol, 2015; 193(4):1163-9.

2Jay White B, Vittal Shenoy, et al. Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-017-0008-7. 

3Beckman Coulter Access Hybritech p2PSA Instructions for Use.

*phi results are intended to be used as an aid in distinguishing prostate cancer from benign prostatic conditions in men 50 years of age and older with total PSA results in the 4-10 ng/mL range and negative digital rectal examination DRE findings.

Biopsy outcomes of patients in the 4-10 ng/mL range.

Indicated for use as an aid in distinguishing prostate cancer from benign prostatic conditions in men aged 50 years and older with total PSA results in the 4-10 ng/mL in the U.S and or the 2-10 ng/mL range outside the U.S.